溢多利(300381) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 198,841,582.87, representing a 9.94% increase compared to CNY 180,859,695.19 in the same period last year[5] - Net profit attributable to shareholders reached CNY 19,630,209.75, a significant turnaround from a loss of CNY 13,677,120.84, marking a 243.53% increase[5] - Basic earnings per share improved to CNY 0.0401, compared to a loss of CNY 0.0279 per share in the same quarter last year, reflecting a 243.73% increase[5] - Operating profit for Q1 2024 was CNY 19.84 million, a significant recovery from a loss of CNY 0.49 million in the same period last year[22] - Net profit for Q1 2024 was CNY 20.04 million, compared to a net loss of CNY 12.45 million in Q1 2023, indicating a turnaround in profitability[24] - The total comprehensive income for Q1 2024 was CNY 17.19 million, recovering from a loss of CNY 11.05 million in Q1 2023[24] Cash Flow - The net cash flow from operating activities was CNY 52,995,539.37, a remarkable increase of 1,561.23% from a negative cash flow of CNY 3,626,771.02 in the previous year[5] - The company's cash flow from operating activities was CNY 225.07 million, compared to CNY 188.12 million in the previous year, showing strong cash generation[26] - The net cash flow from operating activities for Q1 2024 was ¥52,995,539.37, a significant improvement compared to a net outflow of ¥3,626,771.02 in Q1 2023[27] - Total cash inflow from investment activities was ¥260,060,152.19, up from ¥125,994,371.74 in the same period last year[27] - The net cash flow from investment activities was -¥138,031,352.97, contrasting with a positive net flow of ¥58,241,207.39 in Q1 2023[27] - The company reported a cash flow from financing activities net amounting to ¥144,813,408.23, a recovery from a net outflow of ¥10,069,236.85 in Q1 2023[28] Assets and Liabilities - Total assets decreased by 4.57% to CNY 2,953,503,704.94 from CNY 3,094,935,260.92 at the end of the previous year[5] - Total liabilities decreased to CNY 280.75 million from CNY 359.79 million year-over-year, indicating improved financial health[22] - The company's total equity decreased slightly to CNY 2.67 billion from CNY 2.74 billion year-over-year, reflecting changes in retained earnings and other comprehensive income[22] - The company experienced a 99.70% decrease in credit impairment losses, amounting to CNY 6,732,108.50, due to a reduction in accounts receivable[9] - The company reported a significant reduction in accounts payable, decreasing to CNY 59.65 million from CNY 57.47 million, indicating better management of liabilities[22] Investments and Acquisitions - The company completed the acquisition of a 30% stake in Hunan Meikeda Biological Resources Co., Ltd. for a transaction price of 80 million RMB, with an assessed value of 266.75 million RMB[13] - The company established a subsidiary in Russia to enhance its international marketing network[16] - The company received EU product registration for its endo-1,4-beta-xylanase, allowing entry into the EU market[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,273[12] - Zhuhai Jindadi Investment Co., Ltd. holds 30.97% of shares, totaling 151,767,378 shares, with 39,600,000 shares pledged[12] Research and Development - Research and development expenses increased to CNY 22.00 million, up from CNY 19.80 million, reflecting a focus on innovation[22] Inventory and Fixed Assets - The company’s inventory increased slightly from 195,721,802.07 RMB to 197,724,139.67 RMB, an increase of about 1.02%[20] - The company’s fixed assets increased from 649,092,130.25 RMB to 702,773,556.13 RMB, an increase of approximately 8.3%[20] Other Financial Metrics - Cash and cash equivalents increased by 22.70% to CNY 56,214,231.45, attributed to higher cash receipts from sales and the release of restricted bank deposits[11] - The company's cash and cash equivalents decreased from 669,159,454.39 RMB to 517,269,915.51 RMB, a decline of approximately 22.7%[20] - The company completed the board and supervisory board elections on April 3, 2024[17]